Actually, Evamist sales are running at about 5% of expected peak, so far, which is not very good more than a year after the product's launch. Evamist has been a serious disappointment, so far.
I stand by my argument that its breadth of products makes Acrux a better defensive investment than most biotechs, but quite a bit now hinges on Axiron.
ACR Price at posting:
$1.30 Sentiment: LT Buy Disclosure: Held
